Physician profile
Tom C Hsu
NPI 1285854729
$1,307.26
in general payments reported to CMS, 2019-2025
13 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $323 · 2023: $81.94 · 2024: $77.12 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $485.08 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $205.37 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $143.64 | 2019-2025 | |
| Abbvie INC. | $91.88 | 2025 | |
| New World Medical,INC. | $67.60 | 2023 | |
| Alcon Vision LLC | $65.21 | 2025 | Rocklatan |
| Aerie Pharmaceuticals, INC. | $61.84 | 2019-2020 | |
| Shire North American Group INC | $44.22 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.29 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $27.47 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $20.17 | 2025 | Vyzulta |
| Kala Pharmaceuticals, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.